From Stalled to Signed Deals Mini-Book
How Healthcare Sales Leaders Win Executive Access and Close Multi-Million Dollar Deals with the C-Suite Selling System
Most companies believe their challenge is getting in the door with hospital executives. It is not. The real challenge is what happens next.
Access without strategy leads to stalled deals, endless follow ups, and opportunities that quietly disappear. The organizations that consistently win at the executive level do something fundamentally different. They understand the market at a deeper level, they bring a clear point of view, and they know how to guide a decision, not just present a solution.
This mini-book is about how to do that.
It is a practical framework for navigating complex hospital sales, where decisions are shaped by financial pressure, regulatory demands, and competing priorities across the organization. You will learn what it actually takes to get in front of the C Suite, how to structure your first interaction so it matters, and how to build a system that keeps deals moving forward instead of stalling.
If you are selling into healthcare, this is not about selling more. It is about selling differently, at the level where the most important decisions are made.
Inside this mini-book:
What It Really Takes to Get in Front of Hospital Executives
Know the market better than anyone in the room
Stand out by bringing a point of view
Orchestrate the first presentation like it is your only shot
Why Your Best Deals Keep Stalling and What to Do About It
Issue 1: There is no re engagement system
Issue 2: You have optimism without a strategy
Issue 3: You are missing the organizational dynamics
How to Know Where Your Deals Stand
The 5 Step C Suite Selling System
Step 1: Get clear on what you are selling
Step 2: Connect what you sell to what is happening in the market
Step 3: Elevate your message to the executive level
Step 4: Build sales materials and train the team to use them
Step 5: Build the system to prevent stalls before they start
C Suite Selling is not easy and that is the point
Introduction
Every sales leader has had a deal that’s been “in committee” for six months.
The story likely sounds something like this.
One of my clients had a significant multi-year, seven-figure deal on the line with a major health system. The CFO had reached out because they’d identified a gap, knew they needed help, and wanted a solution. My client’s on-site demonstration went well, as did meetings with multiple stakeholder groups. By every visible measure, the deal was moving forward.
Then, it stalled.
There was no dramatic objection or competing vendor announcement, just a gradual pause.
The health system’s responses took a little longer, and the team kept extending the timeline. Updates sounded reasonable, but nothing moved closer to closing. When we finally got to the bottom of it, the reason for the stall was simple: The health system decided to conduct an internal audit of its workflows before layering in a new solution.
This was completely reasonable, but also completely outside my client’s control.
So, the deal sat still for months while that process unfolded.
Stalled deals sound like a soft “maybe,” not a hard “no.”
A stalled deal isn’t a lost opportunity, but an absence of forward motion (with a plausible-sounding reason and a timeline no one can pin down).
The updates say the deal is in review, or that the slow timeline is part of the normal internal process. But with every passing week, the executive’s priorities shift a little further, and the momentum that took months to build drains away. At companies that sell medical devices, technology, and services to major health systems, this is not an edge case.
Between 40 and 60 percent of enterprise pipelines are stalled at any given time.
So, most sales organizations have learned to absorb that as a cost of doing business rather than as a problem to be solved.
I know this because I spent two decades on both sides of it—founding, growing, and successfully exiting a healthcare consulting firm that won against billion-dollar companies. Now, I work directly with the sales organizations to close the deals I used to be on the other end of.
The stalled deal problem is not a mystery. It’s a pattern, and it’s fixable.
The reason your deals stall is that you lack consistent, repeatable access to the C-suite and a system to move them forward.
Those two problems compound each other, and the result is a pipeline full of opportunities that should be closed and aren’t.
It’s worth being direct about what’s at stake.
The financial impact is the obvious part—stalled deals are unrecognized revenue, unmet growth mandates, and missed board commitments. For PE-backed companies operating on three- to five-year hold horizons, every significant stalled deal is a direct threat to the exit multiple. For publicly held companies, the effect on shareholder accountability is real and visible.
But there’s a less quantifiable cost that matters just as much: market credibility.
Landing a major health system is a signal. Consistently failing to close the enterprise deals your team has worked to develop is also a signal. Executives at peer health systems pay attention to these signals, as do boards.
For the sales team itself, the cost is personal. High-performing reps who can’t get consistent access or can’t close the deals they work hard to develop don’t stay forever. They go to a company where the system works. The organizational damage from that (in lost relationships, institutional knowledge, and team morale) is harder to recover from than any single stalled deal.
The deals that do close at the C-suite level open a different kind of opportunity altogether.
When a healthcare company becomes a trusted partner to a health system’s executive leadership, the relationship expands in ways that transactional deals never do. They lead to co-development opportunities, long-term contracts, and relationships that make the next enterprise deal easier to close. That’s what most companies are aiming for, but the path there runs directly through the stalled deal problem.
This mini-book is about what it takes to fix both C-suite access and stalled deals.
In the pages ahead, you’ll learn:
● What it takes to earn consistent C-suite access at major health systems and why most companies are approaching it wrong
● Why your most important deals keep stalling, and the three strategic issues that are almost always behind stalled deals
● How to diagnose where each stalled deal stands before it drifts too far to recover, and the five-step C-Suite Selling System that moves deals from stalled to signed
By the end, you’ll understand how to spot, unstick, and close stalled deals. You’ll get a framework for rethinking how your organization approaches C-suite access and deal velocity, built from my direct experience selling into (and now consulting for) some of the largest health systems in the country.
Let’s begin.
What It Really Takes to Get in Front of Hospital Executives
Too many healthcare sales leaders believe C-suite access is a volume game.
Sales reps just need to do more networking, send more cold emails, and focus on follow-up. Even worse, they assume their company’s brand name will open doors on its own.
Neither works at the executive level.
Hospital Chief Financial Officers, Chief Medical Officers, and Chief Clinical Officers are navigating one of the most complex operating environments in history. New CMS (Centers for Medicare & Medicaid Services) mandates, shifting reimbursement structures, tariff pressures, and institution-specific strategic priorities mean that every vendor relationship carries higher stakes than it did five years ago.
The vendors who earn their trust aren’t the ones who show up in their inbox most often. They show up knowing what’s at stake.
That’s why the most successful healthcare sales teams consistently do three things:
1. Know the market better than anyone in the room.
A hospital CFO fielding dozens of vendor outreach attempts every week has one filter that cuts through everything:
Does this person understand my world, or are they here to explain their product to me?
Surface-level industry knowledge is enough for a conversation with a department director or a mid-level administrator. It’s not enough for the boardroom. C-suite executives think at the level of institutional strategy, financial performance, and regulatory exposure. If a sales rep can’t speak that language with credibility, the meeting ends—politely, professionally, and without a follow-up.
Two recent CMS initiatives illustrate this gap.
The Rural Health Transformation (RTH) Program and the Transforming Episode Accountability Model (TEAM) initiative are both mandates that a significant percentage of health systems must now respond to. The health systems affected are actively working through the implications. Most vendors selling into those systems don’t know them well enough to be useful in that conversation.
As a sales rep, that knowledge is your opening.
It’s not because the information is secret. (It’s publicly available on the Medicare website, in CMS presentations, and in the audio recordings of policy briefings.) The opening exists because almost no one on the vendor side does the work to stay up to date on industry-specific information.
For example, I was recently giving a sales presentation to the Chief Medical Officer of one of the largest health systems in the country. The conversation turned to a specific CMS ruling about beneficiary incentives—how hospitals can now offer patients certain incentives tied directly to outcomes without it constituting inducement. The CMO wasn’t aware of it. But I was. That single moment shifted the entire dynamic of the meeting, moving it from a vendor pitch to an advisory conversation.
That is what genuine market knowledge does at the executive level.
You become useful in a way that nobody else in the room expects.
2. Stand out by bringing a point of view.
Hospital executives hear the same claims from dozens of vendors every month.
“We can help you save money, reduce risk, and improve outcomes!”
The language is nearly identical across companies, categories, and pitches. The vendors who get remembered (and called back) arrive with a unique perspective on the problem. This isn’t product claims repackaged as insights, but a genuine point of view:
● An insight the executive hasn’t considered
● A framing of a problem that changes the conversation
● A truth about their organization that they haven’t been able to see
Here’s an example of what this looks like in practice. In the purchased services category—vendor contracts and outsourced services—there’s a fundamental visibility problem that most hospital finance teams don’t know they have. Enterprise Resource Planning (ERP) systems capture what was paid. They don’t capture what was inside the invoice. With purchased services, there’s no purchase order line, SKU, or receiving record. Every rate, every unit count, every billed quantity lives inside the invoice document and nowhere else.
Finance only sees a total, and that total gets processed and paid.
Most healthcare CFOs are accountants by training who care deeply about the details. But they have no idea this visibility issue exists. Neither do their consultants and vendors, who work with the same aggregated spend data, like contract benchmarking and category comparisons. All of it relies on totals, instead of the actual line items where potential savings live.
You can’t save what you can’t see.
Almost nobody sees this issue. But this one POV—you can’t save what you can’t see—has opened more C-suite conversations than any amount of outreach or follow-up could have for my clients and me. Especially when delivered clearly, backed by specifics, and offered without hedging.
A point of view like that doesn’t come from a positioning exercise or a messaging workshop.
It comes from genuinely knowing the customer’s world and being willing to put in the hard work to root out the problem and design a different solution.
3. Orchestrate the first presentation like it’s your only shot.
The first sales presentation is where your deal either converts into a relationship or ends.
I’m a strong believer that this is the most underestimated moment in the entire sales process. Most companies treat it like a formality. Those who close enterprise deals treat it as a strategic asset.
Unfortunately, most first presentations go something like this: There are 10 people on the call, and the first 20 minutes are spent on company history (the founding story, team bios, and headcount). By the time the reason for the meeting surfaces, the executive has mentally checked out.
You earn or lose a room in the first 90 seconds.
C-suite leaders don’t wait for the second half of a deck to decide if a conversation is worth their time. They make that call almost immediately. And most presentations give them every reason to move on.
To earn the room, lead with the big idea.
Share the specific insight you uncovered, the problem that matters right now, or the thing that makes the executive lean forward.
Instead of saying “let me tell you about our company,” say “here’s what we’ve seen across health systems like yours, and here’s why it matters right now.” Give concrete examples, specific numbers, and actual situations over hypotheticals.
Here’s what that looks like in practice:
● With clients, I’ll often open with something like: “You’re evaluating implants on cost per case, but the real value is whether they enable procedures you’re not doing today.”
● Or: “You’ve invested in automation, but your teams are still doing manual work because the data isn’t connected where decisions are made.”
Neither of those is a product claim, but both changed the conversation immediately.
The executives I’ve most respected have done the same thing at scale.
Glen Tullman built Livongo on a single reframe: people with diabetes don’t want to be more engaged with their disease—they want to spend less time on it. That one line challenged the chronic disease management industry’s core assumption before he ever mentioned a product.
Gary Guthart, the CEO of Intuitive Surgical, never pitched the da Vinci system as a robot. His reframe was that the story wasn’t the cost of the equipment. It was the total cost of patient care, and how a well-run robotics program is often the most profitable thing a hospital runs. That shift, from capital expense to financial outcome, is what turned a $1.5 million piece of equipment into a C-suite conversation.
A reframe makes the executive see their situation differently and earns the room.
But earning the room is only half the job. The close of that first sales presentation matters just as much as the open.
● A team that ends with “let us know if you have any questions” has handed control of the relationship back to the buyer.
● A team that ends with a specific, low-friction request—”If you can share this particular data set, we’ll run an analysis and send you back your own numbers with our findings within two weeks”—has done something fundamentally different.
A request gives the executive a reason to stay engaged. So the next step is your responsibility, not the executive’s. Asking for something instead of waiting for something is often the difference between a deal that moves forward and one that stalls.
Getting C-suite access is step one.
Having consistent C-suite access is hard, and many sales teams never achieve it reliably.
But another important aspect of C-suite selling that often gets overlooked is that the quality of your pre-presentation work affects what happens after the meeting.
Companies that invest in deep market knowledge, a differentiated point of view, and a strong first presentation tend to see fewer stalled deals. When deals do stall, they recover faster because the executive already sees them as a trusted voice. This means re-engagement is a continuation of a relationship rather than a cold restart.
That said, deals can still stall when C-suite access is done well.
The executive goes quiet, and follow-up emails go unanswered. The pipeline update sounds the same as last week. A lot of sales organizations don’t have a clear explanation for why or a system for what to do about it.
Let’s fix that.
Why Your Best Deals Keep Stalling, and What to Do About It
A stalled deal rarely announces itself.
It tends to dissolve slowly, with each update sounding vaguely reasonable:
“It’s still in review.”
“We’re waiting on the committee.”
“They’re just slow. It’s a long sales cycle.”
All of these excuses normalize stalled deals. They’re accounted for in forecasts, explained away in pipeline reviews, and treated as an inevitable part of selling into large healthcare systems. The team rationalizes the situation enough that action feels premature.
By the time you recognize a deal as truly stalled, you’ve already lost meaningful leverage.
After working with healthcare sales organizations for decades, I’ve seen the same issues repeatedly stall deals. They’re not always apparent, and they’re rarely named directly. But they’re often misdiagnosed as timing problems, when they’re almost always strategy problems.
Here are the most common issues that lead to stalled deals:
Issue #1: There’s no re-engagement system.
Most re-engagement is an email: “Just wanted to see if there were any updates on your end.”
That kind of outreach creates no urgency and adds no value to the executive’s world. What unsticks a stalled deal is a specific, relevant reason that gives the executive cause to move forward.
I’m a big believer that the best re-engagement strategy isn’t reactive.
It starts during the first presentation, before a deal has any chance to stall.
As the meeting comes to a close, give a simple request: Send us one specific data set, and we’ll run an analysis and come back with our findings. This should be something the team can easily pull, like a canned report. You don’t want to make it too labor-intensive.
If a deal stalls, an early data exchange becomes the re-entry point.
An executive who went quiet three months ago will read an email that says, “Based on the preliminary analysis we ran on your data, we’ve identified $1.5 million in opportunity. This is a first pass. Once we begin the engagement, we expect it to be significantly more. Would you like to reconnect next week?”
Speculative claims from a vendor are easy to ignore. But you can’t argue with your own data.
A specific finding based on the hospital’s own numbers is invaluable for moving a deal forward.
Other re-engagement tools that work are thought leadership tied directly to a regulatory or competitive shift the executive is actively navigating, peer benchmarking that shows how comparable health systems have addressed the same challenge, and a well-timed prompt that reconnects the executive’s personal strategic goals to what your solution delivers.
Issue #2: You have optimism without a strategy.
Sales cultures are optimistic by nature.
That’s not a criticism—optimism is part of what makes a high-performing team function. But unchecked optimism about stalled deals is expensive. When the team believes a deal is still alive because the executive hasn’t said no, risks go unaddressed. Competitive activity goes unmonitored. The executive’s shifting internal priorities (budget cycles, leadership changes, or new initiatives that have displaced yours) don’t get surfaced in time to respond.
One of the most valuable shifts a sales organization can make is learning to ask:
What could go wrong here?
This is a proactive discipline, not a reason to catastrophize. If you know the risks, you can address them before they become deal-killers. If you don’t, you find out when it’s too late to do anything about it.
To do this, ask strong questions in every executive interaction.
Don’t ask: “How are things going?” Instead, ask: “What’s changed in your priorities over the last 60 days?” Not “are we still on track?” but “is there anything that could slow down the decision on your end?”
To do this well, you have to pay close attention to the competitive landscape. Because in healthcare, a vendor that’s moving while you’re waiting is the one that wins.
Issue #3: You’re missing the organizational dynamics.
Deals at the C-suite level stall because the buying environment inside a health system is genuinely complex.
There are:
● Committee structures that move slowly
● Multiple decision-makers with competing priorities
● Internal champions who may want the deal to happen but don’t have the organizational influence to push it forward on their own
To work through this, ask: Does our internal champion have what they need to advocate for this deal when we’re not in the room?
A healthcare executive who was enthusiastic in your presentation still has to sell the decision internally to peers, the board, and budget owners. If they don’t have a clear, concise way to explain the value (or if the ROI case isn’t defensible under scrutiny), the deal stalls in committee. It’s not because the executive changed their mind, but because they ran out of ways to communicate your value.
This is exactly what happened with the client I mentioned at the start of this book.
The deal had been progressing well—they gave a strong on-site demonstration, had productive meetings with multiple stakeholder groups, and got genuine executive interest. Then, the health system decided to conduct a thorough internal audit of its own workflows. It was the right decision for them, but it meant months of internal work they had to build from scratch.
So, our response was to offer something they could actually use.
We’ve reached out and said:
“As you’re auditing your own process, would you like to see how other hospitals have done the same? We definitely have a process and a framework that hospitals have used. Would this be helpful?”
Right away, they answered, “It would absolutely be helpful.”
They were essentially building the audit from scratch. My guess is that it was tough to even start the audit because they had to map it out. So this gave them a framework for how others have done it. It was in a really nice, very well-designed, very well-written document. They used it and absolutely loved it.
Most importantly, it helped them complete their audit and continue with my client in the process.
Soon, the stalled deal was unstuck.
The principle is the same one that runs through every effective re-engagement strategy: Be useful in a way no one else is. Don’t do this in a generic “we’re here if you need us” sense, but be specifically useful in the context of what the executive is working on (and worried about) right now.
How to Know Where Your Deals Stand
Not all stalled deals are the same.
Treating them as if they are is one of the most common and costly mistakes a sales organization can make. Understanding where a deal sits on the spectrum determines what you can still do about it. A useful way to think about this is a simple traffic light framework:
● Green zone: The deal is paused but warm. The executive is still reachable, the relationship is intact, and proactive re-engagement can accelerate it. These are your highest-leverage opportunities, and they should be treated as such.
● Yellow zone: The decision timeline is slipping. The risk of reprioritization or competitive entry is real. The window for easy recovery is closing, and what’s needed is a targeted re-engagement strategy—not another check-in.
● Red zone: The deal has stalled long enough that competition has entered, executive focus has shifted, and margin concessions start to look tempting. Recovery is difficult and expensive. Sometimes, the right answer is a graceful exit rather than a desperate push.
The traffic light framework is simple to use, but it requires an honest assessment that optimistic sales cultures aren’t always wired to do on their own. Most companies don’t have a system to diagnose which “zone” their deal is in. This means they apply the same tactics to a red-zone deal as a green one, and then wonder why nothing moves.
A simple starting point is to pull every deal in your pipeline that hasn’t moved in the past 30 days or more, assign each one a zone, and then look for patterns. Most sales leaders find the distribution more concerning than they expected. That’s often the moment when the stalled-deal problem stops feeling abstract.
Once you know where your deals get stuck, you can begin building the system to fix it.
The 5 Step C-Suite Selling System
The following five steps are as much a thought exercise as a framework.
As you work through them, keep your own company in mind. Notice when the answers come easily and when they don’t. These gaps often lead to stalled deals.
This is the process I developed over two decades of selling into health systems myself, and the same process I now use with clients to help them build consistent C-suite access and close the deals that matter.
The goal is to help you see your own commercial situation through a different lens.
Step 1: Get clear on what you’re selling.
Before messaging, deck design, or access strategy, you need a deep understanding of what you sell, where it fits in a health system’s world, and what problem it solves at the executive level.
This sounds obvious, yet it’s almost never clear.
A lot of companies can describe their products. Very few can articulate how it connects to the strategic priorities of a CFO, a CMO, or a Chief Clinical Officer. And fewer still can map it to what that specific executive is personally accountable for this year. There’s a significant difference between the two, and that difference determines whether you’re having a supply chain conversation or a C-suite conversation.
A spine company I worked with is a good example. They had been stuck selling to supply chain for years and had solid relationships at the department level, but no traction at the executive table. When we dug into what their product did, something different emerged: the technology enabled access to a net-new surgical population, patients who previously weren’t candidates for surgery at all.
That’s not a cost reduction story. That’s a top-line revenue story, and it’s a conversation for a CFO who has to report growth to the board. The product hadn’t changed, just the understanding of where it fit.
The questions to ask your own team:
● What is our flagship offering, and what is its highest-value application in a health system context?
● Who does it impact beyond the department that uses it directly (supply chain, reimbursement, operations, patient outcomes)?
● What does a health system executive have to believe to say yes, and do we have a clear path to helping them get there?
The companies that can answer these questions are the ones getting in front of the executive who can say yes.
Step 2: Connect what you sell to what’s happening in the market.
Once you understand your product in depth, the next step is to connect it to the external environment—the regulatory shifts, competitive pressures, and institutional priorities that shape executives’ decision-making right now.
Most companies do a version of this for their marketing materials.
That’s not what this step is about.
This is about your reps knowing the market well enough to teach it, not just to mention it. They have to walk into a CFO’s office and surface something the executive hasn’t seen or thought of yet. This requires staying on top of insights and industry trends.
Most companies won’t do deep industry research, which is exactly how you stand out.
For example, I discovered the TEAM Initiative—a significant CMS mandate—through a client engagement. I was working with a company that had a cardiac surgery product, doing a deep dive into everything their product touched. Through that research, I came across the TEAM program before most people in the market were talking about it. That knowledge became a differentiator not just in one meeting, but across multiple engagements where executives hadn’t yet mapped the mandate to their own operations.
That’s the level of market depth this step requires. It typically takes three to four weeks of focused research to build properly. In my experience, the companies that invest in this work show up to C-suite conversations with information nobody else is bringing. That changes the dynamic before you’ve said a word about your product.
You can ask these questions to pressure-test:
● What CMS or regulatory changes are directly relevant to what you sell, and do your reps know them well enough to explain the implications — not just name them?
● What is the competitive landscape inside the health systems you’re targeting, and are your real differentiators built into how the team sells or just into the product brochure?
● What are the specific strategic priorities of the systems on your target list, and how much of that is publicly available in annual reports, board presentations, or leadership interviews?
When you or your reps know something the executive doesn’t, the entire dynamic of the conversation shifts in your favor before you’ve said a word about your product.
Step 3: Elevate your message to the executive level.
Armed with product depth and market intelligence, the third step is translating that into a message that resonates specifically with C-suite leaders.
C-suite executives think in terms of strategic priorities, financial performance, competitive positioning, and institutional reputation. They are not looking for a product demonstration. They are looking for a perspective that helps them see their own situation more clearly, and a credible path to the outcomes they’re accountable for.
I’m a big believer in writing thought leadership directed at what a hospital CFO or CMO needs to know.
Don’t share generic industry content. Give a specific perspective on the decisions that are live for executives in that role right now. Directors and VPs below the C-suite will read it too, because they want to anticipate what their leadership cares about. You never lose by writing to the executive level. You always lose by writing below it.
The questions to work through:
● What are your genuine points of view that executives would find useful or surprising?
● What does a peer health system leader already know, and what can you tell them that they don’t? The gap between those two is where the conversation gets interesting.
● Does your message speak to the specific executive you’re meeting with (their role, accountabilities, and current strategic context), or is it the same message regardless of who’s in the room?
Step 4: Build sales materials and train the team to use them.
Strategy and messaging are only valuable if they translate into materials the sales team can use. This is where many organizations lose the work they’ve done in the first three steps.
There are two common failure modes.
The first is creating generic materials that can’t be customized to a specific health system or executive. The second is creating excellent materials and then failing to train the team on how to use them. So reps fall back on the familiar generic deck that wasn’t working in the first place.
Here’s what a well-built set of materials looks like in practice:
● A first presentation designed to open with the big idea and the executive’s priorities
● A follow-up sequence built to prevent stalls, including a specific data request that keeps momentum in the team’s court
● Custom data assets built around a specific health system’s own numbers, gaps, opportunities, and situation
● A train-the-trainer model: one internal expert who understands the strategy deeply enough to coach the broader team
Remember, the market is constantly changing. So you have to stay up to date on new mandates, competitive shifts, and executive priorities. The best engagements include a mechanism for keeping the materials current rather than treating them as a finished product.
Step 5: Build the system to prevent stalls before they start.
The most valuable work happens before a deal gets the chance to stall.
Companies that consistently close at the enterprise level build an orchestration system around every active deal. Consider this a relationship-management and re-engagement protocol that keeps the executive engaged while always keeping the ball in your team’s court.
This is where the bake-off strategy becomes relevant.
When I ran VIE Healthcare, I once competed against much larger firms for a significant five-year contract with a well-known health system. All three companies under consideration provided similar services, and the health system struggled to differentiate among them on paper. Instead of waiting for them to figure it out, I suggested a bake-off.
Give all three of us the same, small pilot project and see the work in real time.
I knew my competitors couldn’t move as fast as we could. We completed a thorough analysis with detailed findings in two weeks, while the other firms dragged it out. The health system didn’t need to rely on promises or presentations to make the decision. They’d seen the work.
We won the five-year contract.
Two years later, a different health system found itself in the same situation. I offered the same suggestion, and we got the same outcome.
The principle behind the bake-off is the same one behind the data request after the first presentation. Don’t wait for the buyer to figure it out. Give them a reason to move, and make that reason concrete.
The questions every deal team should be able to answer:
● What happens after the first meeting? What specific ask does the team make that keeps the next step on their plate rather than the buyer’s?
● What are the early warning signs that a deal is moving from the green to the yellow zone, and what’s the response plan when that happens?
● Does each executive in the buying process have what they need to advocate for the deal internally? What would make that easier for them?
Now, you can’t prevent every stalled deal. In a complex buying environment, some deals will stall regardless. The goal is to reduce them significantly, catch them early when they do occur, and never let a green-zone deal drift to red because no one was paying attention.
C-Suite Selling Is Not Easy, And That’s The Point
“This is not easy” is one of the first things I say to clients before we begin working together.
Selling to the C-suite at major health systems is among the most demanding tasks a healthcare sales organization can undertake. It requires a depth of market knowledge most teams haven’t built, a precision of message most pitches don’t achieve, and a level of orchestration—across access, positioning, first presentation, and post-meeting follow-through—that very few organizations have turned into a repeatable system.
That’s not a criticism of the people doing the work.
The sales leaders and commercial officers I work with are talented, motivated, and deeply committed to growing their companies. The problem isn’t effort. It’s that nobody handed them a system that works at this level, and building one from scratch while managing a pipeline, a team, and a board is genuinely hard.
But over two decades, I’ve consistently seen the companies that build this system close different deals. They get longer contracts, stronger partnerships, and relationships with health system executives that expand over time. Those companies stop competing on price because they’re no longer being evaluated the same way as everyone else.
The ones that don’t build the system keep absorbing stalled deals as a cost of doing business—until the missed growth mandates, the lost talent, or the pressure from a board or a PE timeline makes that no longer an option.
The path from where most companies are to where they want to be is not a mystery.
It’s a system, and it’s buildable.
The companies that create a C-suite selling system become the vendor that health system executives call when something important needs to get done.
If you recognize your company in any of these pages, the next step is a conversation.
I work with mid-market and enterprise healthcare companies to build the strategy, messaging, and systems that unlock C-suite access and close the deals that matter. My engagements are customized, intensive, and built around the specific commercial challenges of your organization.
To learn more, visit –
Healthcare Sales Masterclass Training
About Lisa T. Miller, MHA
Lisa T. Miller is a healthcare strategist, commercialization advisor, and former CEO of VIE Healthcare Consulting, a firm she founded in 1999 and grew into one of the Top 10 healthcare consulting firms in the United States. In 2022, VIE was acquired by Morgan Stanley Capital Partners.
Over a 30+ year career, Lisa has built a reputation for closing complex, high-value deals with hospital executives and helping organizations improve financial performance, operational efficiency, and patient outcomes. She developed a proven C-Suite selling framework that combines deep industry knowledge, education-based selling, and precise value articulation—enabling companies to access senior decision makers and secure multi-million-dollar engagements.
Lisa’s work is grounded in a rare dual perspective. She has spent decades inside hospitals advising CEOs, CFOs, COOs, and service line leaders on critical operational and financial decisions, while also building and scaling a national consulting firm that competed successfully against much larger organizations. This gives her a clear understanding of how healthcare organizations function—how decisions are made, where initiatives stall, and what drives action at the executive level.
In addition to her advisory work, Lisa has developed innovative technologies, including her patented Invoice ROI™ system, designed to uncover financial opportunities within complex healthcare spend. She was the host of “The Healthcare Leadership Experience” podcast, recognized as a top healthcare podcast by Feedspot, where she shares insights on margin improvement, operational strategy, and growth.
Today, Lisa advises healthcare organizations and companies that sell into healthcare on strategy, growth, and commercialization. Her focus is on helping leaders translate complexity into clear decisions, align solutions with what health systems value, and pursue opportunities that drive measurable impact.
She is the host of the podcast Selling to Healthcare and publishes a Substack Selling to Hospitals, where she shares insights on C-Suite selling, healthcare economics, and how companies can align with what health systems value.